Measurement of Ocular Blood Flow and Retinal Oxygen Extraction in Diabetic Patients

The National Institutes of Health has added a clinical trial registration (NCT07536516) to ClinicalTrials.gov documenting a study on ocular blood flow and retinal oxygen extraction in diabetic patients. The trial will examine GLP-1 receptor agonists including semaglutide and liraglutide, as well as the dual GIP/GLP-1 agonist tirzepatide, using advanced retinal imaging technologies. This is an observational study without drug administration as an intervention.

For affected parties, this registry entry provides transparency on ongoing research into diabetes-related complications affecting retinal health. Clinical investigators conducting diabetes or ophthalmology research may need to be aware of this competitive research landscape. Patients with diabetes mellitus should note this represents an active investigation into potential retinal protection from GLP-1 based therapies. No compliance obligations or regulatory requirements arise from this registry entry.